Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Significant Increase in Short Interest

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 93,600 shares, an increase of 46.9% from the September 15th total of 63,700 shares. Approximately 2.3% of the company’s shares are sold short. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is currently 0.1 days.

Vivos Therapeutics Trading Up 9.5 %

Shares of VVOS stock traded up $0.22 during trading hours on Friday, reaching $2.53. 85,638 shares of the stock were exchanged, compared to its average volume of 4,138,773. The firm has a market capitalization of $12.07 million, a price-to-earnings ratio of -0.36 and a beta of 7.72. Vivos Therapeutics has a 12-month low of $1.91 and a 12-month high of $48.79. The company’s 50-day moving average price is $2.66 and its 200-day moving average price is $2.56.

Vivos Therapeutics (NASDAQ:VVOS) last announced its earnings results on Wednesday, August 14th. The company reported ($0.60) earnings per share (EPS) for the quarter. The business had revenue of $4.05 million for the quarter. Vivos Therapeutics had a negative net margin of 85.90% and a negative return on equity of 652.32%. On average, sell-side analysts expect that Vivos Therapeutics will post -3.13 EPS for the current year.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets increased their price target on Vivos Therapeutics from $6.40 to $6.60 and gave the company a “buy” rating in a report on Tuesday, August 20th.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.